Clinical trial
A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroids and When Co-Administered With Montelukast in Subjects With Inadequately-Controlled Asthma.
NCT01730027 is registered in ClinicalTrials.gov with Pulmagen Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroids and When Co-Administered With Montelukast in Subjects With Inadequately-Controlled Asthma.
- Lead sponsor
- Pulmagen Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2013
- Completion date
- December 31, 2014
- Enrollment
- 248 (actual)
- Sites
- 87
Conditions
As the registry lists them; a condition with its own page is linked.